Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 22 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2024 | Fruquintinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as FRUZAQLA (DIN 02551462) under ATC L01EK04 FRUQUINTINIB. Indications are not published in the Drug Product Database —… | DIN02551462 | approvedsource: Marketed | health-canada-dpd |
| Oct 30, 2024 | Fruquintinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as FRUZAQLA (DIN 02551454) under ATC L01EK04 FRUQUINTINIB. Indications are not published in the Drug Product Database —… | DIN02551454 | approvedsource: Marketed | health-canada-dpd |
| Oct 28, 2024 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ AFATINIB (DIN 02512793) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database… | DIN02512793 | approvedsource: Marketed | health-canada-dpd |
| Oct 28, 2024 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ AFATINIB (DIN 02512785) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database… | DIN02512785 | approvedsource: Marketed | health-canada-dpd |
| Oct 28, 2024 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ AFATINIB (DIN 02512777) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database… | DIN02512777 | approvedsource: Marketed | health-canada-dpd |
| Oct 21, 2024 | Vorasidenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VORANIGO (DIN 02551233) under ATC L01XM04 VORASIDENIB. Indications are not published in the Drug Product Database —… | DIN02551233 | approvedsource: Marketed | health-canada-dpd |
| Oct 21, 2024 | Vorasidenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VORANIGO (DIN 02551225) under ATC L01XM04 VORASIDENIB. Indications are not published in the Drug Product Database —… | DIN02551225 | approvedsource: Marketed | health-canada-dpd |
| Oct 16, 2024 | Calaspargase Pegol | Health Canada CA | cancer not stated in this record | Marketed in Canada as ASPARLAS (DIN 02542943) under ATC L01 ANTINEOPLASTIC AGENTS. Indications are not published in the Drug Product… | DIN02542943 | approvedsource: Marketed | health-canada-dpd |
| Oct 15, 2024 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02505177) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02505177 | approvedsource: Marketed | health-canada-dpd |
| Oct 8, 2024 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02542005) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02542005 | approvedsource: Marketed | health-canada-dpd |
| Oct 8, 2024 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02528754) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02528754 | approvedsource: Marketed | health-canada-dpd |
| Oct 8, 2024 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02528746) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02528746 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 27, 2024 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-PALBOCICLIB (DIN 02552140) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02552140 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 20, 2024 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as AG-LETROZOLE TABLETS (DIN 02543419) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02543419 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 22, 2024 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION, USP (DIN 02452421) under ATC L01CE02 IRINOTECAN. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 29, 2024 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMATINIB (DIN 02521210) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02521210 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 27, 2024 | Mogamulizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as POTELIGEO (DIN 02527715) under ATC L01FX09 MOGAMULIZUMAB. Indications are not published in the Drug Product Database… | DIN02527715 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 28, 2024 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528789) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Daunorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DAUNORUBICIN HYDROCHLORIDE INJECTION (DIN 02539209) under ATC L01DB02 DAUNORUBICIN. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 18, 2023 | Epcoritamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPKINLY (DIN 02542307) under ATC L01FX27 EPCORITAMAB. Indications are not published in the Drug Product Database —… | DIN02542307 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 30, 2023 | Dabrafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAFINLAR (DIN 02540053) under ATC L01EC02 DABRAFENIB. Indications are not published in the Drug Product Database —… | DIN02540053 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 27, 2024 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-PALBOCICLIB (DIN 02552132) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02552132 | approvedsource: Marketed | health-canada-dpd |
| Sep 27, 2024 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-PALBOCICLIB (DIN 02552124) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02552124 | approvedsource: Marketed | health-canada-dpd |
| Sep 27, 2024 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02547694) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02547694 | approvedsource: Marketed | health-canada-dpd |
| Sep 27, 2024 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02547686) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02547686 | approvedsource: Marketed | health-canada-dpd |
| Sep 17, 2024 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-PALBOCICLIB (DIN 02547651) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02547651 | approvedsource: Marketed | health-canada-dpd |
| Sep 17, 2024 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-PALBOCICLIB (DIN 02547643) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02547643 | approvedsource: Marketed | health-canada-dpd |
| Sep 17, 2024 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-PALBOCICLIB (DIN 02547635) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product… | DIN02547635 | approvedsource: Marketed | health-canada-dpd |
| Sep 12, 2024 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTABLE (DIN 02530635) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug… | DIN02530635 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 20, 2024 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP LETROZOLE TABLETS (DIN 02541912) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02541912 | approvedsource: Marketed | health-canada-dpd |
| Aug 12, 2024 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528800) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN02528800 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 16, 2024 | Atezolizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECENTRIQ SC (DIN 02546310) under ATC L01FF05 ATEZOLIZUMAB. Indications are not published in the Drug Product… | DIN02546310 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 29, 2024 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMATINIB (DIN 02521202) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02521202 | approvedsource: Marketed | health-canada-dpd |
| Apr 24, 2024 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as M-METHOTREXATE (DIN 02534916) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02534916 | approvedsource: Marketed | health-canada-dpd |
| Apr 16, 2024 | Capivasertib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRUQAP (DIN 02544733) under ATC L01EX27 CAPIVASERTIB. Indications are not published in the Drug Product Database —… | DIN02544733 | approvedsource: Marketed | health-canada-dpd |
| Apr 11, 2024 | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLATIRAMER ACETATE INJECTION (DIN 02541440) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in… | DIN02541440 | approvedsource: Marketed | health-canada-dpd |
| Apr 1, 2024 | Capivasertib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRUQAP (DIN 02544741) under ATC L01EX27 CAPIVASERTIB. Indications are not published in the Drug Product Database —… | DIN02544741 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 23, 2024 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION BP (DIN 02536285) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02536285 | approvedsource: Marketed | health-canada-dpd |
| Feb 12, 2024 | Nivolumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as OPDUALAG (DIN 02541416) under ATC L01FY02 NIVOLUMAB AND RELATLIMAB. Indications are not published in the Drug Product… | DIN02541416 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 24, 2024 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NYPOZI (DIN 02521008) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see… | DIN02521008 | approvedsource: Marketed | health-canada-dpd |
| Jan 24, 2024 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NYPOZI (DIN 02520990) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see… | DIN02520990 | approvedsource: Marketed | health-canada-dpd |
| Jan 23, 2024 | Elranatamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELREXFIO (DIN 02543567) under ATC L01FX32 ELRANATAMAB. Indications are not published in the Drug Product Database —… | DIN02543567 | approvedsource: Marketed | health-canada-dpd |
| Jan 23, 2024 | Elranatamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELREXFIO (DIN 02543559) under ATC L01FX32 ELRANATAMAB. Indications are not published in the Drug Product Database —… | DIN02543559 | approvedsource: Marketed | health-canada-dpd |
| Jan 8, 2024 | Eribulin | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ERIBULIN (DIN 02539136) under ATC L01XX41 ERIBULIN. Indications are not published in the Drug Product Database —… | DIN02539136 | withdrawnsource: Dormantsince Jul 2, 2026 | health-canada-dpd |
| Jan 5, 2024 | Plerixafor | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLERIXAFOR INJECTION (DIN 02539454) under ATC L03AX16 PLERIXAFOR. Indications are not published in the Drug Product… | DIN02539454 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 18, 2023 | Epcoritamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPKINLY (DIN 02542293) under ATC L01FX27 EPCORITAMAB. Indications are not published in the Drug Product Database —… | DIN02542293 | approvedsource: Marketed | health-canada-dpd |
| Dec 18, 2023 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTION (DIN 02536293) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02536293 | approvedsource: Marketed | health-canada-dpd |
| Dec 15, 2023 | Brexucabtagene Autoleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TECARTUS (DIN 02532719) under ATC L01XL06 BREXUCABTAGENE AUTOLEUCEL. Indications are not published in the Drug… | DIN02532719 | approvedsource: Marketed | health-canada-dpd |
| Dec 6, 2023 | Relugolix | Health Canada CA | cancer not stated in this record | Marketed in Canada as ORGOVYX (DIN 02542137) under ATC L02BX04 RELUGOLIX. Indications are not published in the Drug Product Database — see… | DIN02542137 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 30, 2023 | Trametinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEKINIST (DIN 02539993) under ATC L01EE01 TRAMETINIB. Indications are not published in the Drug Product Database —… | DIN02539993 | approvedsource: Marketed | health-canada-dpd |